指南与共识骨软组织肉瘤与黑色素瘤

伊马替尼治疗药物监测:IATDMCT共识指南

Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy.
指南 / 共识 · Eur J Cancer · 2021-09-28

国际治疗药物监测与临床毒理学协会(IATDMCT)评估了伊马替尼血药浓度与临床效应相关性的已发表文献,并据此制定伊马替尼治疗药物监测(TDM)共识指南。文章总结了伊马替尼TDM的科学证据及IATDMCT共识推荐。

要点

  • TDM在肿瘤领域尚未广泛接受,伊马替尼等酪氨酸激酶抑制剂仍采用固定剂量给药。
  • 已有多项研究探讨伊马替尼血药浓度与临床效应的相关性。
  • IATDMCT基于现有数据制定伊马替尼TDM共识指南。

核心结论

  • IATDMCT认为有必要评估伊马替尼TDM的已发表文献并基于现有数据制定共识指南。

研究设计与样本

  • IATDMCT组织制定的共识指南,基于对伊马替尼TDM相关已发表文献的评估。

主要发现

  • 已有多项已发表研究探讨伊马替尼血药浓度与临床效应的相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although therapeutic drug monitoring (TDM) is an important tool in guiding drug dosing for other areas of medicine including infectious diseases, cardiology, psychiatry and transplant medicine, it has not gained wide acceptance in oncology. For imatinib and other tyrosine kinase inhibitors, a flat dosing approach is utilised for management of oral chemotherapy. There are many published studies examining the correlation of blood concentrations with clinical effects of imatinib. The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) determined that there was a need to examine the published literature regarding utility of TDM in imatinib therapy and to develop consensus guidelines for TDM based on the available data. This article summarises the scientific evidence regarding TDM of imatinib, as well as the consensus guidelines developed by the IATDMCT.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Clarke WA, Chatelut E, Fotoohi AK, et al. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. Eur J Cancer. 2021. PMID: 34597977. doi:10.1016/j.ejca.2021.08.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。